Nurix Therapeutics Inc. trailing returns
How Nurix Therapeutics Inc. (NRIX) has performed over the last day, week, month and year, over 5 years, and since inception, through October 16, 2026 — price return and dividends side by side, with the worst drop inside each window.
Trailing returns by period#
To 2026-10-16. Price return + dividends = total return. Per year (CAGR) for windows of a year or more, with the cumulative total return beneath. Worst drop: the deepest fall in the price from a high inside the window, and when it bottomed.
| Period | Price | DivsDividends | Total | Worst drop |
|---|---|---|---|---|
| 1 day | -2.1% | +0.0% | -2.1% | — |
| 5 days | +9.3% | +0.0% | +9.3% | -2.1%Oct 16 |
| 1 month | -2.9% | +0.0% | -2.9% | -13.8%Oct 13 |
| YTD | +28.7% | +0.0% | +28.7% | -25.7%Mar 20 |
| 1 year | +143.5% | +0.0% | +143.5% | -32.8%Mar 2026 |
| 5 years | -3.3% | +0.0% | -3.3%-15.3% | -87.7%Oct 2023 |
| Since inception (2020) | +4.1% | +0.0% | +4.1%+28.5% | -91.5%Oct 2023 |
Growth of NRIX#
Actual level with dividends reinvested (solid); dashed lines are each window's constant-rate path from start to today.
- 5 years-3.3%/year · -15.3%
Methodology#
Trailing returns measure from the closest close about N years before the latest close (2026-10-16). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Price return is the change in NRIX's closing price; total return reinvests dividends (from its split- and dividend-adjusted closes); the dividends column is the difference between the two. The worst drop is the largest fall in the closing price from a high to a later low inside the window, the way a drawdown is usually quoted. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.
FAQ#
- What is Nurix Therapeutics Inc.'s return since inception?
- Since 2020, Nurix Therapeutics Inc. (NRIX) has compounded at about +4.1% a year — +28.5% in total.